Adenomatous Polyposis Coli

• 

  Subject Areas on Research

  • A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). 
  • A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. 
  • APC-mediated downregulation of beta-catenin activity involves nuclear sequestration and nuclear export. 
  • Activity level, apoptosis, and development of cachexia in Apc(Min/+) mice. 
  • Age-related vulnerabilities of older adults with colon adenomas: evidence from Project Prevent. 
  • Aggressive fibromatosis (desmoid tumor) is derived from mesenchymal progenitor cells. 
  • An association between the 4G polymorphism in the PAI-1 promoter and the development of aggressive fibromatosis (desmoid tumor) in familial adenomatous polyposis patients. 
  • Attenuated familial adenomatous polyposis: an evolving and poorly understood entity. 
  • CRISPR-SID: Identifying EZH2 as a druggable target for desmoid tumors via in vivo dependency mapping. 
  • Cells with pathogenic biallelic mutations in the human MUTYH gene are defective in DNA damage binding and repair. 
  • Defining the polyposis/colorectal cancer phenotype associated with the Ashkenazi GREM1 duplication: counselling and management recommendations. 
  • Familial adenomatous polyposis and mental retardation caused by a de novo chromosomal deletion at 5q15-q22: report of a case. 
  • Familial adenomatous polyposis-associated desmoids display significantly more genetic changes than sporadic desmoids. 
  • Genetic deletion of receptor for hyaluronan-mediated motility (Rhamm) attenuates the formation of aggressive fibromatosis (desmoid tumor). 
  • Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. 
  • Ileal pouch-anal anastomosis for ulcerative colitis and familial adenomatous polyposis: historical development and current status. 
  • Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. 
  • Morphologic characterization of syndromic gastric polyps. 
  • Overlapping spectra of SMAD4 mutations in juvenile polyposis (JP) and JP-HHT syndrome. 
  • Pancreas-preserving duodenectomy in the management of duodenal familial adenomatous polyposis. 
  • Primary high-grade neuroendocrine carcinoma emerging from an adenomatous polyp in the setting of familial adenomatous polyposis. 
  • Project PREVENT: a randomized trial to reduce multiple behavioral risk factors for colon cancer. 
  • Serum insulin levels and the prevalence of adenomatous and hyperplastic polyps in the proximal colon. 
  • Short bowel syndrome after continence-preserving procedures. 
  • Subtotal colectomy for familial polyposis. A clinical series and review of the literature. 
  • Targeted suppression of beta-catenin blocks intestinal adenoma formation in APC Min mice. 
  • The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.